Researchers compare the therapeutic efficacy of risakizumab and ustekinumab for the treatment of moderate-to-severe Crohn’s disease.
Risankizumab outperforms ustekinumab in treating moderate-to-severe Crohn’s disease
- Post author:
- Post published:August 23, 2024
- Post category:uncategorized